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1. INTRODUCTION AND BACKGROUND 
 
1.1  The need for new vaccine against tuberculosis 
 
Tuberculosis (TB) kills about three million people annually. It is estimated that one third of the 
world’s population are latently infected with Mycobacterium tuberculosis (M.tb). Multi-drug 
resistant strains of M.tb, and co-infection with M.tb and HIV present major new challenges. The 
currently available vaccine, M. bovis BCG, is largely ineffective at protecting against adult 
pulmonary disease in endemic areas and it is widely agreed that a new more effective 
tuberculosis vaccine is a major global public health priority1. However, it may be unethical and 
impractical to test and deploy a vaccine strategy that does not include BCG, as BCG does confer 
worthwhile protection against TB meningitis and leprosy. An immunisation strategy that 
includes BCG is also attractive because the populations in which this vaccine candidate will need 
to be tested will already have been immunised with BCG.   
M.tb is an intracellular organism. CD4+ Th1-type cellular responses are essential for protection 
and there is increasing evidence from animal and human studies that CD8+ T cells also play a 
protective role2. However, it has generally been difficult to induce strong cellular immune 
responses in humans using subunit vaccines. DNA vaccines induce both CD4+ and CD8+ T cells 
and thus offer a potential new approach to a TB vaccine. DNA vaccines encoding various 
antigens from M. tuberculosis have been evaluated in the murine model, and to date no DNA 
vaccine alone has been shown to be superior to BCG3,4.  
A heterologous prime-boost immunisation strategy involves giving two different vaccines, each 
encoding the same antigen, several weeks apart. Such regimes are extremely effective at 
inducing a cellular immune response. Using a DNA- prime/MVA-boost immunisation strategy 
induces high levels of CD8+ T cells in animal models of malaria and HIV5,6, and high levels of 
both CD4+ and CD8+ T cells in animal models of TB7.  BCG immunisation alone induces only 
CD4+ T cells in mice. A prime-boost strategy using BCG as the prime and a recombinant MVA 
encoding an antigen from M.tb that is also present in BCG (antigen 85A: ‘MVA85A’) as the 
boost, induces much higher levels of CD4+ T cells than BCG or MVA85A alone. In addition, 
this regime generates specific CD8+ T cells that are undetectable following immunisation with 
BCG alone. 
 
1.2  Recombinant viruses as vaccines.  
 
Recombinant viruses used alone have for some years represented a promising vaccine delivery 
system, particularly for inducing cellular immune responses8. The recombinant virus encodes the 
immunising protein or peptide. Immunisation by a recombinant virus vaccine occurs when host 
cells take up and express the inoculated attenuated virus encoding a protective antigen9. The 
expressed protein often has the native conformation, glycosylation, and other post-translational 
modifications that occur during natural infection. Recombinant viral vaccines may elicit both 
antibody and cytotoxic T-lymphocyte responses10, which persist without further immunisations. 
Many viruses have been investigated as potential recombinant vaccines. The successful 
worldwide eradication of smallpox via vaccination with live vaccinia virus highlighted vaccinia 
as a candidate for recombinant use11,12,13. The recognition in recent years that non-replicating 
strains of poxvirus such as MVA and avipox vectors can be more immunogenic than traditional 
replicating vaccinia strains has enhanced the attractiveness of this approach. MVA (modified 
vaccinia virus Ankara) is a strain of vaccinia virus which has been passaged more than 570 times 
though avian cells, is replication incompetent in human cell lines and has a good safety record. It 
has been administered to more than 120,000 vaccinees as part of the smallpox eradication 
programme, with no adverse effects, despite the deliberate vaccination of high risk groups14,15 . 
This safety in man is consistent with the avirulence of MVA in animal models16. MVA has six 
major genomic deletions compared to the parental genome severely compromising its ability to 
replicate in mammalian cells17. Viral replication is blocked late during infection of cells but 
importantly viral and recombinant protein synthesis is unimpaired even during this abortive 
infection18. Replication-deficient recombinant MVA has been seen as an exceptionally safe viral 
vector19,20. When tested in animal model studies recombinant MVAs have been shown to be 
avirulent, yet protectively immunogenic as vaccines against viral diseases and cancer6,21,22,23,24. 
The most useful data on the safety and efficacy of various doses of a recombinant MVA vaccine 
comes from clinical trial data with a recombinant MVA expressing a number of CTL epitopes 
from Plasmodium falciparum pre-erythrocytic antigens fused to a complete pre-erythrocytic 
stage antigen, Thrombospondin Related Adhesion Protein (TRAP). These trials have given a 
total of 169 immunisations with this recombinant MVA, to 49 UK vaccinees 38 Gambian 
vaccines (20 of whom were children aged 1-5).  6 doses of 1 x 107 pfu, 139 doses of 5 x 107 pfu, 
6 doses of 1 x 108 pfu and 18 doses of 2.5 x 108 pfu have been administered, all without serious 
adverse effects.   
 
1.3  Recombinant MVA encoding antigen 85A 
 
Secreted antigens from M. tuberculosis are released from actively metabolising bacteria, and are 
important targets in protective immunity25. Antigen 85A is a major secreted antigen from M. 
tuberculosis which forms part of the antigen 85 complex (A, B and C).  This complex constitutes 
a major portion of the secreted proteins of both M.tb and BCG. It is involved in fibronectin 
binding within the cell wall and has mycolyltransferase activity26.  
MVA85A induces both a CD4+ and a CD8+ epitope when used to immunise mice. When mice 
are primed with BCG and then given MVA85A as a boost, the levels of CD4+ and CD8+ T cells 
induced are higher than with either BCG or MVA85A alone.   
We are evaluating the safety and immunogenicity of the following 3 groups: 
1. BCG alone 
2. MVA85A alone 
3. BCG prime-MVA85A boost 
 
BCG-BCG provides a control group for BCG-MVA85A. Many countries have a tradition of 
repeated BCG vaccination and the criteria for revaccination differ between countries27.  
 
2. DESCRIPTION OF THE STUDY 
 
2.1 Study Objective 
 
To assess the safety and immunogenicity of BCG delivered intradermally into the deltoid region 
in volunteers who have received BCG 10 - 20 years previously. 
 
 
2.2 Selection of volunteers 
  
Volunteers for the study will be recruited through advertisements. Each volunteer will have 
received an information sheet concerning the study and will have agreed to participate in writing. 
Volunteers will be given at least 48 hours between reading the information leaflet and agreeing 
to participate. Female volunteers will be told of the theoretical risk of congenital anomaly should 
they become pregnant during the study and only those who undertake to take precautions to 
avoid pregnancy during the study period will be eligible. Volunteers will give signed consent for 
their GP’s to be notified about their participation in the trial. The GP will be faxed a letter on the 
day of screening and asked to reply if they know of a reason why the volunteer should not take 
part. The signed consent form will also be faxed with the letter. 
 
 
2.3  Screening  
 
Volunteers will be asked to sign the informed consent form for screening. The following will be 
performed: 
• Medical history and examination 
• Laboratory evaluations – including clinical chemistry, haematology, HLA typing, anti-
HBV antibodies, anti-HCV antibodies, anti-HIV antibodies  
• Heaf test – to exclude prior exposure to TB 
• Urinalysis and urine pregnancy test if female 
 
2.4  Inclusion Criteria 
• Healthy adult aged 18-55 years. 
• Normal medical history and physical examination. 
• Normal urine dipstick, blood count, liver enzymes, and creatinine. 
 
2.5  Exclusion Criteria 
 
a. Exposure to TB at any point. A positive ESAT6/CFP10 Elispot response (defined as 
greater than 5 spots/well above background and at least double the background 
response). 
b. Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, 
immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, 
liver disease, renal disease, gastrointestinal disease, neurological illness, psychiatric 
disorder, drug or alcohol abuse.  
c. Oral or systemic steroid medication or the use of immunosuppressive agents. 
d. Positive HIV antibody test, HCV antibody test or positive HBV serology except post-
vaccination. 
e. Heaf test greater than Grade II 
f. Confirmed pregnancy 
 
2.6  Withdrawal Criteria 
 
a. Withdrawal of consent by subject for any reason 
b. Loss to follow-up 
c. Non-compliance with study procedures 
d. Protocol violation 
e. Serious adverse event (as defined in Appendix 3) 
f. Any other reason at discretion of the Principal Investigator 
g. Confirmed pregnancy during study period 
 
 
2.7  Immunisation 
 
On Day 0, subjects will receive a single intradermal injection of 0.1ml BCG over the deltoid 
muscle. Vital signs will be monitored at 30 and 60 minutes post-immunisation. Local reactions at 
the site of administration will be evaluated at 60 minutes.  
 
A photograph of the injection site may be taken at 48 hours (with written consent). The injection 
site will be reviewed 7 days after each immunization.  
 
Blood will be taken at the following time points: At the screening visit*, prior to the vaccination, 
1 week after the first vaccination*, 2 weeks, 4 weeks, 8 weeks, 12 weeks* and 24 weeks after the 
vaccination. Up to 55 mls will be taken at any one time with the total being no more than 500 
mls over the study period. *Samples taken on these dates will be tested for full blood count and 
biochemical screen. Immunological assays will be performed at all time points to determine 
vaccine immunogenicity. A pregnancy test will be performed prior to vaccination for female 
volunteers.  Peripheral blood mononuclear cells will be prepared for cellular immunological 
assays to be performed without or following cryopreservation. Other serological measures of 
immune response, i.e. antibody titres, will be assayed on frozen plasma samples. 
All blood tests will be taken within 1-3 days of the due date as described in the schedule above. 
 
At the 24 week timepoint, a Heaf test will be repeated in order to document the change (if any) in 
Heaf responsiveness after the second BCG vaccination.  
 
 
2.8  Endpoints 
 
The occurance and severity of local side-effects 
The occurance and severity of systemic side-effects 
The induction of T cell responses (as measured by an interferon-gamma Elispot assay). 
Proliferation assays and cytotoxic T cell assays will be performed on strong CD4+ and CD8+ 
responses respectively. 
 
2.9  Adverse Events 
 
See Appendix 1. 
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APPENDIX 1 
 
ADVERSE EVENTS 
 
1. Definition and Grading Intensity of Adverse Events 
 
An adverse event is defined as any unintended change in the body structure (signs) or body 
function (symptoms), whether or not considered related to test product. During the entire study, 
subjects will be instructed to report all adverse events. All adverse events, whether volunteered, 
elicited or noted on physical examination, will be recorded throughout the study. 
 
The severity of adverse events will be categorized as follows: 
 • MILD  =  Experience that is minor and does not cause significant 
discomfort to subject or change in activities of daily living (ADLs); 
subject is aware of symptoms but symptoms are easily tolerated. 
 • MODERATE  =  Experience is an inconvenience or concern to the subject 
and causes interference with ADLs but the subject is able to continue with 
ADLs. 
 • SEVERE  =  Experience significantly interferes with ADLs and the 
subject is incapacitated and/or unable to continue with ADLs. 
 
2. Criteria for Determining Relationship to Test Product 
 
The Investigator will make a determination of the relationship of the adverse event to the test 
product. The relationship to test product of all adverse events will be classified according to the 
following guidelines: 
 • NOT RELATED  =  Data available to clearly identify an alternative cause 
of the reaction, e.g., hemorrhage due to mechanical injury. 
 • UNLIKELY 
  •• Reasonable temporal relation to vaccination, BUT 
  •• Unlabeled/unexpected reaction, AND 
  •• The reaction can be reasonably explained by other factors (such as 
interventions), AND 
  •• Negative de-challenge, if available, OR 
  •• No reasonable temporal relation to vaccination. 
 
 
 • POSSIBLE 
  •• Reasonable temporal relation to vaccination, AND 
  •• Labeled/expected reaction, OR 
  •• Unlabeled/unexpected reaction, BUT 
  •• Other factors could have caused or contributed to the reaction 
(such as subject’s clinical state, concomitant therapy, and/or other 
interventions). 
 • PROBABLE 
  •• Reasonable temporal relation to vaccination, AND 
  •• Labeled/expected reaction, AND 
  •• The reaction cannot be reasonably explained by other factors (such 
as the subject’s clinical state, concomitant therapy, and/or other 
interventions). 
 • HIGHLY PROBABLE 
  •• Reasonable temporal relation to vaccination, AND 
  •• Labeled/expected reaction, AND 
  •• The reaction cannot be reasonably explained by other factors (such 
as the subject’s clinical state, concomitant therapy, and/or other 
interventions), AND 
  •• Positive de-challenge, if applicable, AND 
  •• Positive re-challenge, OR 
  •• Application/vaccination site reaction. 
 
3 Definition of Reportable Events 
 
The following adverse events are considered “serious reportable adverse events:”  
 
 • Death of a subject or life threatening events. 
 • Hospitalization (other than elective procedures or outpatient observation 
of <24 hour duration) or prolongation of hospitalization. 
 • Cancer or congenital anomaly. 
 • Chronic or permanent disability. 
 • Overdose. 
 • Any serious adverse event (i.e., an adverse event that is graded as serious 
or life-threatening in appendix 2). 
 
 
 
 
 
APPENDIX 2 
 
Table for Grading Severity of Adult Adverse Experiences for Vaccine Trials 
 
Guidelines 
 
ABBREVIATIONS:  Abbreviations utilized in this Table include: 
ULN =Upper Limit of Normal   LLN =Lower Limit of Normal 
Rx =Therapy    Req =Required 
Mod =Moderate    IV =Intravenous 
ADL =Activities of Daily Living  Dec =Decreased 
 
ESTIMATING SEVERITY GRADE 
For abnormalities NOT found elsewhere in the Toxicity Table use the scale below to estimate grade of severity: 
GRADE 1 Mild  Transient or mild discomfort (< 48 hours); no medical 
intervention/therapy required. 
GRADE 2 Moderate Mild to moderate limitation in activity – some assistance may 
be needed; no or minimal medical intervention/therapy required. 
GRADE 3 Severe  Marked limitation in activity, some assistance usually 
required; medical intervention/therapy required, hospitalization possible. 
GRADE 4 Life- threatening Extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care 
probable. 
 
SERIOUS OR LIFE-THREATENING Adverse Events 
ANY clinical event deemed by the clinician to be serious or life-threatening should be considered a Grade 4 Adverse 
Event.  Clinical events considered to be serious or life-threatening include, but are not limited to:  seizures, coma, 
tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, 
severe depression. 
 
MISCELLANEOUS 
• When two values are used to define the criteria for each parameter, the lowest values will appear first. 
• Parameters are generally grouped by body system. 
• Some protocols may have additional protocol specific grading criteria. 
 
 
APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse Experiences 
for Vaccine Trials 
 
Parameter Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Grade 4 
Potentially 
Life-Threatening 
POTASSIUM 
  Hyperkalemia 
  Hypokalemia 
 
5.0 – 5.5 meq/L 
3.2 – 3.4 meq/L 
 
5.6 – 6.0 meq/L 
2.9 – 3.1 meq/L 
 
6.1 – 6.5 meq/L 
2.5 – 2.8 meq/L 
 
>6.5 meq/L 
<2.5 meq/L 
PHOSPHATE 
Hypophosphatemia 
 
2.0 – 2.4 mg/dL 
 
1.5 – 1.9 mg/dL 
 
1.0 – 1.4 mg/dL 
 
<1.0 mg/dL 
CALCIUM – (corrected 
for albumin) 
  Hypocalcemia 
  Hypercalcemia 
 
 
7.8 – 8.4 mg/dL 
10.6 – 11.5 mg/dL 
 
 
7.0 – 7.7 mg/dL 
11.6 – 12.5 mg/dL 
 
 
6.1 – 6.9 mg/dL 
12.6 – 13.5 mg/dL 
 
 
<6.1 mg/dL 
>13.5 mg/dL 
MAGNESIUM 
  Hypomagnesemia 
 
1.2 – 1.4 meq/L 
 
0.9 – 1.1 meq/L 
 
0.6 – 0.8 meq/L 
 
<0.6 meq/L 
BILIRUBIN 
  Hyperbilirubinemia 
 
>1.0 – 1.5 x ULN 
 
>1.5 – 2.5 x ULN 
 
>2.5 – 5 x ULN 
 
>5 x ULN 
GLUCOSE 
  Hypoglycemia 
  Hyperglycemia 
(nonfasting and no prior 
diabetes) 
 
55 - 84 mg/dL 
118 – 160 mg/dL 
 
40 – 54 mg/dL 
161 - 250 mg/dL 
 
30 -39 mg/dL 
251 – 500 mg/dL 
 
<30 mg/dL 
>500 mg/dL 
Triglycerides ---- 400 - 750 mg/dL 751 – 1200 mg/dL >1200 mg/dL 
URIC ACID 
  Hyperuricemia 
 
7.5 – 10.0 mg/dL 
 
10.1 – 12.0 mg/dL 
 
12.1 – 15.0 mg/dL 
 
>15.0 mg/dL 
LIVER TRANS- 
AMINASE (LFTs) 
  AST (SGOT) 
  ALT (SGPT) 
  GGT 
  Alk Phos 
 
 
1.25 – 2.5 x ULN 
1.25 – 3.0 x ULN 
1.25 – 2.5 x ULN 
1.25 – 2.5 x ULN 
 
 
>2.5 – 5.0 x ULN 
>3.0 – 5.0 x ULN 
>2.5 – 5.0 x ULN 
>2.5 – 5.0 x ULN 
 
 
>5.0 – 10.0 x ULN 
>5.0 – 10.0 x ULN 
>5.0 – 10.0 x ULN 
>5.0 – 10.0 x ULN 
 
 
> 10.0 x ULN 
> 10.0 x ULN 
> 10.0 x ULN 
> 10.0 x ULN 
PANCREATIC 
ENZYMES 
  Amylase 
  Pancreatic amylase 
  Lipase 
 
 
>1.0 – 1.5 x ULN 
>1.0 – 1.5 x ULN 
>1.0 – 1.5 x ULN 
 
 
>1.5 – 2.0 x ULN 
>1.5 – 2.0 x ULN 
>1.5 – 2.0 x ULN 
 
 
>2.0 – 5.0 x ULN 
>2.0 – 5.0 x ULN 
>2.0 – 5.0 x ULN 
 
 
>5.0 x ULN 
>5.0 x ULN 
>5.0 x ULN 
 
APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse Experiences 
for Vaccine Trials  
 
Parameter Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Grade 4 
Potentially 
Life-Threatening 
CARDIOVASCULAR 
Cardiac 
Arrhythmia 
 
 
------------ 
Asymptomatic; 
transient dysrhythmia, 
no Rx req 
Recurrent/persistent 
dysrhythmia; 
symptomatic Rx req 
Unstable 
dysrhythmia, 
hospitalization and 
Rx req 
Hypertension Transient, increase >20 mm 
Hg diastolic BP; no Rxreq 
Recurrent; chronic 
increase >20 mm Hg 
diastolic BP;  Rx req  
Acute Rx req; outpatient OR 
hospitalization possible 
Hospitalization req 
OR end organ 
damage 
Hypotension Transient orthostatic 
hypotension with heart rate 
increased by >20 beats/min 
OR decreased by <10 mm 
Hg systolic BP, no Rx req 
Symptoms OR BP 
decreased by <20 mm 
Hg systolic, correctable 
with oral fluid Rx 
IV fluid req OR 
hospitalization 
Mean arterial 
pressure <60 mm 
Hg, OR end organ 
damage, OR 
shock, vasopressor 
Rx req 
Pericarditis Minimal effuision Mild/mod 
asymptomatic effusion, 
no Rx 
Symptomatic effusion, pain, 
EKG changes 
Tamponade OR 
pericardiocentesis 
OR surgery req 
Hemorrhage, 
blood loss 
 
------------ 
Mildly symptomatic, no 
Rx req 
Gross blood loss OR 1-2 
units transfused 
Massive blood 
loss OR >2 units 
transfused 
GASTROINTESTINAL 
Nausea Mild OR transient; 
reasonable intake maintained 
Mod discomfort OR 
intake decreased for <3 
days 
Severe discomfort OR 
minimal intake for >3 days 
Hospitalization req 
Vomiting Mild OR transient; 2-3 
episodes per day OR mild 
vomiting lasting <1 week 
Mod OR persistent; 4-5 
episodes per day; OR 
vomiting lasting > week 
Severe vomiting of all 
food/fluids in 24 hrs OR 
orthostatic hypotension OR 
IV Rx req 
Hypotensive shock 
OR hospitalization 
req for IV Rx req 
Diarrhea Mild OR transient; 3-4 loose 
stools per day OR mild 
diarrhea lasting <1 week 
Mod OR persistent; 5-
10 loose stools per day 
OR diarrhea lasting >1 
week 
>10 loose stools/day bloody 
diarrhea; OR orthostatic 
hypotension OR electrolyte 
imbalance, >2 L IV fluid req 
Hypotensive shock 
OR severe 
electrolyte 
imbalance 
Oral Discomfort/ 
Dysphagia 
Mild discomfort, no 
difficulty swallowing 
Difficulty swallowing 
but able to eat and drink 
Unable to swallow solids Unable to drink 
fluids; IV fluids 
req 
Constipation  
 
------------ 
Moderate abdominal 
pain 78 hours with 
impaction require 
outpatient prescription 
Requiring disimpaction or 
hospital treatment 
Distention with 
vomiting OR 
obstipation 
 
APPENDIX 2 – Modified Table for Grading Severity of Adult Adverse Experiences for Vaccine 
Trials  
 
Parameter Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Grade 4 
Potentially Life-
Threatening 
Cough (for aerosol 
studies) 
Transient; no Rx Treatment associated 
cough; inhaled 
bronchodilator 
Uncontrolled cough; 
systemic Rx req 
 
--------------- 
Bronchospasm Acute Transient; no Rx; 
FEV1 or peak flow 
reduced to 70% - 80% 
Rx req; normalizes with 
bronchodilator; FEV1 or 
peak flow 50% - 69% 
No normalization with 
bronchodilator; FEV1 or 
peak flow 25% - 49%, 
retractions 
Cyanosis; FEV1 or 
peak flow <25% 
OR intubated 
Dyspnea Dyspnea on exertion  Dyspnea with normal 
activity  
Dyspnea at rest Dyspnea requiring 
O2 therapy 
NEUROLOGICAL 
Neuro-cerebellar Slight incoordination 
OR 
Dysdiadochokinesia 
Intention tremor OR 
dysmetria OR slurred 
speech OR nystagmus 
Ataxia requiring assistance 
to walk or arm 
incoordination interfering 
with ADLs 
Unable to stand 
Neuro-psych/mood  
 
--------------- 
 
 
--------------- 
Severe mood changes 
requiring medical 
intervention; suicidal 
ideation 
Acute psychosis 
req hospitalization 
; suicidal 
gesture/attempt 
Parasthesia (burning, 
tingling, etc.) 
Mild discomfort; no Rx 
req 
Mod discomfort; non-
narcotic analgesia required 
Severe discomfort; OR 
narcotic analgesia req with 
symptomatic improvement 
Incapacitating; OR 
not responsive to 
narcotic analgesia 
Neuro-motor Mild weakness in 
muscle of feet but able 
to walk and/or mild 
increase or decrease in 
reflexes 
Mod weakness in feet 
(unable to walk on heels 
and/or toes), mild 
weakness in hands, still 
able to do most hand tasks 
and/or loss of previously 
present reflex or 
development of 
hyperreflexia and/or 
unable to do deep knee 
bends to  weakness 
Marked distal weakness 
(unable to dorsiflex toes or 
foot drop, and mod proximal 
weakness e.g., in hands 
interfering with ADLs 
and/or requiring assistance 
to walk and/or unable to rise 
from chair unassisted 
Confined to bed or 
wheel chair 
because of muscle 
weakness 
Neuro-sensory Mild impairment 
(decreased sensation, 
e.g., vibratory, 
pinprick, hot/cold in 
great toes) in focal 
area or symmetrical 
distribution 
Mod impairment (mod 
decreased sensation, e.g., 
vibratory, pinprick, 
hot/cold to ankles) and/or 
joint position or mild 
impairment that is not 
symmetrical 
Severe impairment 
(decreased or loss of 
sensation to knees or wrists) 
or loss of sensation of at 
least mod degree in multiple 
different body sites (i.e., 
upper and lower extremities) 
Sensory loss 
involves limbs and 
trunk 
 
APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse Experiences 
for Vaccine Trials  
 
Parameter Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Grade 4 
Potentially  
Life-Threatening 
Arthralgia/Arthritis Arthralgia Arthralgia with joint 
effusion or moderate 
impairment of activity 
Frank arthritis with or 
without effusion OR 
resulting in severe 
impairment of activity 
 
 
--------------- 
Myalgia Myalgia without 
limitation of activity 
Muscle tenderness at 
other than injection site 
or with moderate 
impairment of activity 
Frank myonecrosis OR 
with severe impairment 
of activity 
 
 
--------------- 
SKIN 
Skin (vaccination site) Refer to Appendix 4 for evaluation of specific changes at site of vaccination 
Skin (general) Scattered macular or 
papular eruption or 
erythema that is 
asymptomatic 
Scattered macular or 
papular eruption or 
erythema with pruritus 
or other associated 
symptoms 
Generalized 
symptomatic macular, 
papular, or vesicular 
eruption 
Exfoliative dermatitis 
or ulcerating dermatitis 
URINALYSIS 
Proteinuria: 
  Random urine 
 
1+ 
 
2 - 3+ 
 
4+ 
 
Nephrotic syndrome 
Proteinuria: 
  24 hour urine 
200 mg - 1 g loss/day 
OR <0.3% OR <3 g/l 
1 – 2 g loss/day OR 
0.3 – 1.0% OR 3 - 10 
g/l 
2 – 3.5 g loss/day OR  
>1.0% OR > 10 g/l 
Nephrotic syndrome 
OR >3.5 g loss/day 
Proteinuria: 
  Hematuria 
Microscopic only <10 
RBC/HPF 
>10 RBC/HPF Gross, with or without 
clots OR RBC casts 
Obstructive OR 
transfusion req 
 
 
APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse 
Experiences for Vaccine Trials  
 
Parameter Grade 1 
Mild 
Grade 2 
Moderate 
Grade 3 
Severe 
Grade 4 
Potentially 
Life-Threatening 
MISCELLANEOUS 
Fever 
  Oral>12 hours 
37.7 - 38.9°C 
(100.0 – 101.5°F) 
39.0 – 39.5°C 
(101.6 – 102.9°F) 
OR max temp of 
103°F 
39.8 – 40.5°C 
(103 - 105°F) 
OR max temp of 
103.5°F 
>40.5°C (105°F) 
OR max temp of >105°F 
Headache Mild, no Rx req, OR non-
narcotic analgesia Rx 
Mod; OR responds to 
initial narcotic Rx 
Severe; intractable; OR 
requiring repeated 
narcotic Rx 
Requiring hospitalization, 
associated with neurologic, 
respiratory or 
cardiovascular 
abnormalities 
Allergic Reaction Pruritus without rash at 
injection site 
Localized urticaria at 
injection site 
Generalized urticaria 
angioedema 
Anaphylaxis 
ADL Normal activity reduced 
<48 hours 
Normal activity 
reduced 25 - 50% >48 
hours 
Normal activity reduced 
>50%; cannot work >48 
hours 
Unable to care for self 
Eye  Mild pain, visual 
changes, conjunctival 
erythema, abnormal 
slit lamp 
Loss of vision, clinically 
diagnosed uveitis, mod-
severe pain, glaucoma 
 
 
--------------- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
